Teva Pharmaceutical (Israel) Story
| TEVA Stock | ILA 4,978 25.00 0.50% |
About 61% of Teva Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in Teva Pharmaceutical Industries suggests that many traders are alarmed regarding Teva Pharmaceutical's prospects. Teva Pharmaceutical's investor sentiment overview provides quick insight into current market opportunities from investing in Teva Pharmaceutical Industries. The current market sentiment, together with Teva Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use Teva Pharmaceutical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Teva Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Teva daily returns and investor perception about the current price of Teva Pharmaceutical Industries as well as its diversification or hedging effects on your existing portfolios.
Teva |
Requested story not found. it has been either deleted or moved. View all stories for Teva Pharmaceutical Industries.
Teva Pharmaceutical Latest Timeline
Teva Pharmaceutical is currently traded for 4,978on Tel Aviv Stock Exchange of Israel. The company has price-to-book ratio of 1.18. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Teva Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.67. The entity recorded a loss per share of 0.56. The firm last dividend was issued on the 28th of November 2017. Teva Pharmaceutical had 2:1 split on the 27th of June 2004.Check out Teva Pharmaceutical Hype Analysis, Teva Pharmaceutical Correlation and Teva Pharmaceutical Performance. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |